Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2523355 vs Ixabepilone in Metastatic Breast Cancer
NCT01416389Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of litronesib in breast cancer, sponsored by Eli Lilly and Company. Started Aug 2011; status: completed.
02
Drugs
litronesib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01416389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416389.